InterContinental Hotel and Conference Center
9801 Carnegie Avenue | Cleveland, OH 44106
May 15, 2014 | 10:30 a.m. - 5:15 p.m.
May 16, 2014 | 8 a.m. - 5:30pm
*Includes meals and conference materials
Meeting Description and Purpose
Fibromuscular dysplasia is an uncommon non-atherosclerotic arterial disorder that is associated with major vascular morbidity, including hypertension, stroke, arterial aneurysm and arterial dissection. More than 90% of patients with FMD are female and the average age at the time of diagnosis is 52 years. Though initially described in 1938, the underlying pathophysiology and genetics of this disorder remains unknown and the prevalence of FMD in the general (female) population is uncertain. The accuracy and cost effectiveness of various imaging modalities to detect and assess severity of FMD remains largely unknown. There have been no randomized clinical trials which have investigated the relative benefit of medical versus interventional therapy for treatment of arterial occlusive or aneurysmal lesions in FMD.
This meeting will gather key researchers and clinical thought leaders in the field of FMD for a state-of-the-art review of the existing knowledge base and current research activities related to FMD in the United States and abroad. A large proportion of the meeting will be focused on the creation of an FMD research network, comprised of four focused working groups on various aspects of FMD research (epidemiology, genetics, research registries, and imaging and clinical therapeutics).
The goal of this meeting is to establish a multi-disciplinary collaborative FMD research network and set an agenda of research priorities with subsequent funding and execution plans to significantly advance knowledge of the understanding of FMD while improving evidence-based care for FMD patients. Small group interaction among working group members with specialized expertise in FMD clinical care and/or the specific research disciplines will discuss research priorities and propose a roadmap of research initiatives moving forward. The genetics working group will meet to determine best use of existing biorepositories of stored blood samples. There will be substantial effort to publicize the discussions of the conference and maximize future research collaborations.
The proposed audience for this conference includes vascular specialists and other clinicians who care for patients with FMD (e.g., neurologists, nephrologists).